Citations

Clear

9383 citation(s) found for "Thomas, PS".

Idiopathic Interstitial Pneumonia
Flaherty, Kevin R. , Andrei, Adin‐Cristian , King, Talmadge E. , Raghu, Ganesh , Colby, Thomas V. , Wells, Athol U. , Bassily, Nadir, Brown, Kevin K. , Bois, Roland du, Flint, Andrew , Gay, Steven E., Gross, Barry H., Kazerooni, Ella A. , Knapp, Robert H., Louvar, Edmund, Lynch, David A. , Quick, John S., Vyskocil, J , Wadenstorer, Frazer A., Wilt, Jeffrey, Toews, Galen B., Murray, Susan , Nicholson, Andrew G. , Thannickal, Victor J. , Travis, William D. , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | January 25, 2007 | Volume: 175 | Issue: 10 | Pages: 1054-1060

10.1164/rccm.200606-833oc | PMID 17255566 Get It

Abstract Rationale Treatment and prognoses of diffuse parenchymal lung diseases (DPLDs) varies by diagnosis. Obtaining a uniform diagnosis among observers is difficult. Objectives Evaluate diagnostic agreement between academic and community-based physicians for patients with DPLDs, and determine if an interactive approach between clinicians, radiologists, and pathologists improved diagnostic agreement in community and academic centers. Methods Retrospective review of 39 patients with DPLD. A total of 19 participants reviewed cases at 2 community locations and 1 academic location. Information from the history, physical examination, pulmonary function testing, high-resolution computed tomography, and surgical lung biopsy was collected. Data were presented in the same sequential fashion to three groups of physicians on separate days. Measurements and Main Results Each observer's diagnosis was coded into one of eight categories. A κ statistic allowing for multiple raters was used to assess agreement in diagnosis. Interactions between clinicians, radiologists, and pathologists improved interobserver agreement at both community and academic sites; however, final agreement was better within academic centers (κ = 0.55–0.71) than within community centers (κ = 0.32–0.44). Clinically significant disagreement was present between academic and community-based physicians (κ = 0.11–0.56). Community physicians were more likely to assign a final diagnosis of idiopathic pulmonary fibrosis compared with academic physicians. Conclusions Significant disagreement exists in the diagnosis of DPLD between physicians based in communities compared with those in academic centers. Wherever possible, patients should be referred to centers with expertise in diffuse parenchymal lung disorders to help clarify the diagnosis and provide suggestions regarding treatment options.
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication
Fuchs, Julia , Kachergus, Jennifer M., Munz, Marita, Schüle, Birgitt , Langston, J. William, Middleton, Frank A. , Ross, Owen A. , Hulihan, Mary , Gasser, Thomas , Farrer, Matthew J. , Nilsson, Christer C. , Larsson, Elna‐Marie , Ross, Owen A

Mayo Clinic

Neurology | January 25, 2007 | Volume: 68 | Issue: 12 | Pages: 916-922

10.1212/01.wnl.0000254458.17630.c5 | PMID 17251522 Get It

Signaling through Gαi2 protein is required for recruitment of neutrophils for antibody-mediated elimination of larvalStrongyloides stercoralisin mice
Padigel, Udaikumar M. , Stein, Louis H. , Redding, Kevin , Lee, James J. , Nolan, Thomas J. , Schad, Gerhard A., Birnbaumer, Lutz , Abraham, David

Mayo Clinic

Journal of Leukocyte Biology | January 23, 2007 | Volume: 81 | Issue: 4 | Pages: 1120-1126

10.1189/jlb.1106695 | PMID 17242370 Get It

AbstractThe heterotrimeric guanine nucleotide-binding protein Gαi2 is involved in regulation of immune responses against microbial and nonmicrobial stimuli. Gαi2−/− mice have a selectively impaired IgM response consistent with a disorder in B cell development yet have augmented T cell effector function associated with increased production of IFN-γ and IL-4. The goal of the present study was to determine if a deficiency in the Gαi2 protein in mice would affect the protective immune response against Strongyloides stercoralis, which is IL-4-, IL-5-, and IgM-dependent. Gαi2−/− and wild-type mice were immunized and challenged with S. stercoralis larvae and analyzed for protective immune responses against infection. Gαi2−/− mice failed to kill the larvae in the challenge infection as compared with wild-type mice despite developing an antigen-specific Th2 response characterized by increased IL-4, IL-5, IgM, and IgG. Transfer of serum collected from immunized Gαi2−/− mice to naïve wild-type mice conferred passive protective immunity against S. stercoralis infection thus confirming the development of a protective antibody response in Gαi2−/− mice. Differential cell analyses and myeloperoxidase assays for quantification of neutrophils showed a significantly reduced recruitment of neutrophils into the microenvironment of the parasites in immunized Gαi2−/− mice. However, cell transfer studies demonstrated that neutrophils from Gαi2−/− mice are competent in killing larvae. These data demonstrate that Gαi2 signaling events are not required for the development of the protective immune responses against S. stercoralis; however, Gαi2 is essential for the recruitment of neutrophils required for host-dependent killing of larvae.
Magnetic Resonance Imaging of Alzheimer's Pathology in the Brains of Living Transgenic Mice: A New Tool in Alzheimer's Disease Research
Jack, Clifford R. , Marjańska, Małgorzata , Wengenack, Thomas M., Reyes, Denise A., Curran, Geoffrey L., Preboske, Gregory M., Poduslo, Joseph F., Garwood, Michael , Lin, Joseph , Jack, Clifford R , Marjańska, Małgorzata

Mayo Clinic

The Neuroscientist | January 17, 2007 | Volume: 13 | Issue: 1 | Pages: 38-48

10.1177/1073858406295610 | PMID 17229974 Get It

Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Cardinal pathologic features of AD are amyloid plaques and neurofibrillary tangles, and most in the field believe that the initiating events ultimately leading to clinical AD center on disordered metabolism of amyloid beta protein. Mouse models of AD have been created by inserting one or more human mutations associated with disordered amyloid metabolism and that cause early onset familial AD into the mouse genome. Human-like amyloid plaque formation increases dramatically with age in these transgenic mice. Amyloid reduction in humans is a major therapeutic objective, and AD transgenic mice allow controlled study of this biology. Recent work has shown that amyloid plaques as small as 35 μm can be detected using in vivo magnetic resonance microimaging (MRMI) at high magnetic field (9.4 T). In addition, age-dependent changes in metabolite concentration analogous to those that have been identified in human AD patients can be detected in these transgenic mice using single-voxel 1 H magnetic resonance spectroscopy ( 1 H MRS) at high magnetic field. These MR-based techniques provide a new set of tools to the scientific community engaged in studying the biology of AD in transgenic models of the disease. For example, an obvious application is evaluating therapeutic modification of disease progression. Toward the end of this review, the authors include results from a pilot study demonstrating feasibility of using MRMI to detect therapeutic modification of plaque progression in AD transgenic mice.
Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations
Pittock, Sean J. , Reindl, Markus , Achenbach, Sara J., Berger, Thomas , Brück, Wolfgang , König, Fatima, Morales, Yazmín, Lassmann, Hans , Bryant, S., Moore, S. Breanndan, Lucchinetti, Claudia F. , Odia, Yazmín , Keegan, B. Mark , Pittock, S J , Odia, Yazmin

Mayo Clinic

Multiple Sclerosis Journal | January 17, 2007 | Volume: 13 | Issue: 1 | Pages: 7-16

10.1177/1352458506072189 | PMID 17294606 Get It

Controversy exists regarding the pathogenic or predictive role of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with multiple sclerosis (MS). Four immunopathological patterns (IP) have been recognized in early active MS lesions, suggesting heterogeneous pathogenic mechanisms. Whether MOG antibodies contribute to this pathological heterogeneity and potentially serve as biomarkers to identify specific pathological patterns is unknown. Here we report the frequencies of antibodies to human recombinant MOG (identified by Western blot and enzymelinked immunoabsorbent assay (ELISA)) in patients with pathologically proven demyelinating disease, and investigate whether antibody status is associated with clinical course, HLA-DR2 genotype, IP or treatment response to plasmapheresis. The biopsy cohort consisted of 72 patients: 12 pattern I, 43 pattern II and 17 pattern III. No association was found between MOG antibody status and conversion to clinically definite MS, DR-2 status, IP or response to plasmapheresis. There was poor agreement between Western blot and ELISA (kappa=0.07 for MOG IgM). Fluctuations in antibody seropositivity were seen for 3/4 patients tested serially by Western blot. This study does not support a pathologic pattern-specific role for MOG-antibodies. Variable MOG-antibody status on serial measurements, coupled with the lack of Western blot and ELISA correlations, raises concern regarding the use of MOG-antibody as an MS biomarker and underscores the need for methodological consensus.
Mammographic Breast Density as a General Marker of Breast Cancer Risk
Vachon, Celine M. , Brandt, Kathleen R. , Ghosh, Karthik, Scott, Christopher G. , Maloney, Shaun D., Carston, Michael J., Sellers, Thomas A. , Vachon, Celine M. , Pankratz, V. Shane , Scott, Christopher

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 12, 2007 | Volume: 16 | Issue: 1 | Pages: 43-49

10.1158/1055-9965.epi-06-0738 | PMID 17220330 Get It

Abstract Mammographic breast density is a strong risk factor for breast cancer but whether breast density is a general marker of susceptibility or is specific to the location of the eventual cancer is unknown. A study of 372 incident breast cancer cases and 713 matched controls was conducted within the Mayo Clinic mammography screening practice. Mammograms on average 7 years before breast cancer were digitized, and quantitative measures of percentage density and dense area from each side and view were estimated. A regional density estimate accounting for overall percentage density was calculated from both mammogram views. Location of breast cancer and potential confounders were abstracted from medical records. Conditional logistic regression was used to estimate associations, and C-statistics were used to evaluate the strength of risk prediction. There were increasing trends in breast cancer risk with increasing quartiles of percentage density and dense area, irrespective of the side of the breast with cancer (Ptrends < 0.001). Percentage density from the ipsilateral side [craniocaudal (CC): odds ratios (ORs), 1.0 (ref), 1.7, 3.1, and 3.1; mediolateral oblique (MLO): ORs, 1.0 (ref), 1.5, 2.2, and 2.8] and the contralateral side [CC: ORs, 1.0 (ref), 1.8, 2.2, and 3.7; MLO: ORs, 1.0 (ref), 1.6, 1.9, and 2.5] similarly predicted case-control status (C-statistics, 0.64-65). Accounting for overall percentage density, density in the region where the cancer subsequently developed was not a significant risk factor [CC: 1.0 (ref), 1.3, 1.0, and 1.2; MLO: 1.0 (ref), 1.1, 1.0, and 1.1 for increasing quartiles]. Results did not change when examining mammograms 3 years on average before the cancer. Overall mammographic density seems to represent a general marker of breast cancer risk that is not specific to breast side or location of the eventual cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(1):43–9)
Prognosis of Fibrotic Interstitial Pneumonia
Park, Joo Hun , Kim, Dong Soon, Park, I-Nae , Jang, Se Jin , Kitaichi, Masanori, Colby, Thomas V. , Nicholson, Andrew G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | January 11, 2007 | Volume: 175 | Issue: 7 | Pages: 705-711

10.1164/rccm.200607-912oc | PMID 17218621 Get It

Abstract Background To investigate whether the better prognosis of interstitial pneumonias associated with collagen vascular disease (CVD) compared with idiopathic interstitial pneumonia (IIP) is due to higher frequency of the nonspecific interstitial pneumonia (NSIP) pattern in CVD, we compared the outcomes of patients from these two groups with the same histopathologic pattern. Subjects The clinical features and survival of 362 patients (269 with IIP and 93 with CVD) diagnosed using surgical lung biopsy were analyzed. Results The mean survival of the CVD group (131.0 mo) was longer than that of the IIP group (80.5 mo) (p < 0.0001). The patients with usual interstitial pneumonia pattern among the CVD group (n = 36) was younger, female, and predominantly nonsmoking compared with the IIP group (n = 203). Although baseline lung functions were not significantly different, the CVD group survived longer (mean, 177.0 mo) than the IIP group (mean, 66.9 ± 6.5 mo; p = 0.001). By multivariate analysis, younger age, better pulmonary function, and the presence of a CVD were independent prognostic factors. In NSIP pattern, no significant differences in survival, clinical features, or lung function were found between the two groups. Conclusion Our data suggest that the better prognosis of patients in the CVD group is not solely due to the predominance of the NSIP pattern. The prognosis of patients with the usual interstitial pneumonia pattern in CVD is better than in those with idiopathic pulmonary fibrosis, despite the same pathologic pattern. In contrast, in those with an NSIP pattern, the prognosis is similar in both groups.
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship
Dellit, Timothy H., Owens, Robert C., McGowan, John E., Gerding, Dale N. , Weinstein, Robert A. , Burke, John P. , Huskins, W. Charles , Paterson, David L. , Fishman, Neil O., Carpenter, Christopher , Brennan, Patrick J. , Billeter, Marianne, Hooton, Thomas M. , Paterson, David L. , Huskins, W Charles

Mayo Clinic

Clinical Infectious Diseases | December 19, 2006 | Volume: 44 | Issue: 2 | Pages: 159-177

10.1086/510393 | PMID 17173212 Get It

The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota
Pardi, Darrell S. , Loftus, Edward V. , Smyrk, Thomas C. , Kammer, Patricia P., Tremaine, William J., Schleck, C. D., Harmsen, William S. , Zinsmeister, Alan R., Melton, L. Joseph, Sandborn, William J. , Loftus, Edward V

Mayo Clinic

Gut | November 29, 2006 | Volume: 56 | Issue: 4 | Pages: 504-508

10.1136/gut.2006.105890 | PMID 17135309 Get It

Objective: Although the epidemiology of microscopic colitis has been described in Europe, no such data exist from North America. We studied the incidence, prevalence and temporal trends of microscopic colitis in a geographically defined US population. Design and setting: In this population based cohort study, residents of Olmsted County, Minnesota, with a new diagnosis of microscopic colitis, and all who had colon biopsies for evaluation of diarrhoea, between 1 January 1985 and 31 December 2001 were identified. Biopsies were reviewed for confirmation (cases) and to identify missed cases (diarrhoea biopsies). Main outcome measures: Incidence rates, age and sex adjusted to the 2000 US white population. Poisson regression assessed the association of calendar period, age and sex with incidence. Results: We identified 130 incident cases for an overall rate of 8.6 cases per 100 000 person-years. There was a significant secular trend, with incidence increasing from 1.1 per 100 000 early in the study to 19.6 per 100 000 by the end (p<0.001). Rates increased with age (p<0.001). By subtype, the incidence was 3.1 per 100 000 for collagenous colitis and 5.5 per 100 000 for lymphocytic colitis. Collagenous colitis was associated with female sex (p<0.001) but lymphocytic colitis was not. Prevalence (per 100 000 persons) on 31 December 2001 was 103.0 (39.3 for collagenous colitis and 63.7 for lymphocytic colitis). Conclusions: The incidence of microscopic colitis has increased significantly over time, and by the end of the study, the incidence and prevalence were significantly higher than reported previously. Microscopic colitis is associated with older age, and collagenous colitis is associated with female sex.
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma
Alsayed, Yazan, Ngo, Hai T., Runnels, Judith, Leleu, Xavier , Singha, Ujjal K. , Pitsillides, Costas, Spencer, Joel A. , Kimlinger, Teresa K. , Jia, Xiaoying , Lu, Ganwei, Timm, Michael, Côté, Daniel , Veilleux, Israël , Hedin, Karen E. , Roodman, G. David, Kung, Andrew L. , Hideshima, Teru , Lin, Charles P. , Ghobrial, Joanna M. , Kumar, Ashok , Witzig, Thomas E. , Anderson, Kenneth C. , Ghobrial, Irene M.

Mayo Clinic

Blood | November 22, 2006 | Volume: 109 | Issue: 7 | Pages: 2708-2717

10.1182/blood-2006-07-035857 | PMID 17119115 Get It

Abstract The mechanisms by which multiple myeloma (MM) cells migrate and home to the bone marrow are not well understood. In this study, we sought to determine the effect of the chemokine SDF-1 (CXCL12) and its receptor CXCR4 on the migration and homing of MM cells. We demonstrated that CXCR4 is differentially expressed at high levels in the peripheral blood and is down-regulated in the bone marrow in response to high levels of SDF-1. SDF-1 induced motility, internalization, and cytoskeletal rearrangement in MM cells evidenced by confocal microscopy. The specific CXCR4 inhibitor AMD3100 and the anti-CXCR4 antibody MAB171 inhibited the migration of MM cells in vitro. CXCR4 knockdown experiments demonstrated that SDF-1–dependent migration was regulated by the PI3K and ERK/MAPK pathways but not by p38 MAPK. In addition, we demonstrated that AMD3100 inhibited the homing of MM cells to the bone marrow niches using in vivo flow cytometry, in vivo confocal microscopy, and whole body bioluminescence imaging. This study, therefore, demonstrates that SDF-1/CXCR4 is a critical regulator of MM homing and that it provides the framework for inhibitors of this pathway to be used in future clinical trials to abrogate MM trafficking.